What is William Blair's Forecast for DNTH FY2025 Earnings?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at William Blair issued their FY2025 earnings per share (EPS) estimates for shares of Dianthus Therapeutics in a research note issued to investors on Wednesday, July 2nd. William Blair analyst M. Minter expects that the company will post earnings per share of ($3.26) for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. William Blair also issued estimates for Dianthus Therapeutics' FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($2.99) EPS, FY2028 earnings at ($3.11) EPS and FY2029 earnings at ($3.81) EPS.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. The company had revenue of $1.16 million for the quarter, compared to analysts' expectations of $0.81 million.

DNTH has been the topic of a number of other reports. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Robert W. Baird reduced their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Guggenheim reiterated a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Stock Up 4.0%

Shares of NASDAQ:DNTH opened at $19.12 on Friday. The firm has a market cap of $614.74 million, a P/E ratio of -6.64 and a beta of 1.38. Dianthus Therapeutics has a 12 month low of $13.37 and a 12 month high of $32.27. The company's 50-day moving average price is $18.90 and its two-hundred day moving average price is $20.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DNTH. TCG Crossover Management LLC bought a new stake in Dianthus Therapeutics in the fourth quarter valued at about $32,735,000. RA Capital Management L.P. grew its position in shares of Dianthus Therapeutics by 53.6% during the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock worth $52,003,000 after buying an additional 1,000,333 shares during the period. Braidwell LP increased its stake in shares of Dianthus Therapeutics by 144.4% in the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after acquiring an additional 712,902 shares during the last quarter. Vestal Point Capital LP raised its position in shares of Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after acquiring an additional 680,000 shares during the period. Finally, Octagon Capital Advisors LP raised its position in shares of Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after acquiring an additional 363,500 shares during the period. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.